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subjects treated with anacetrapib monotherapy due to an 
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Dunbar, E. M. deGoma, A. L. Baer, W. Karmally, D. S. Donovan, 
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Cholesteryl ester transfer protein (CETP) facilitates the 
net exchange of cholesteryl esters (CEs) and triglycerides 
(TGs)  between HDL particles  and  apoB-containing  lipo-
proteins (1–3). Inhibition of CETP reduces CE and TG ex-
change among lipoproteins, which has effects on the lipid 
composition  of  lipoproteins  as  well  as  their  metabolism 
(4–6). CETP inhibition is associated with increased levels 
of HDL-cholesterol (HDL-C) and reduced levels of LDL- 
cholesterol (LDL-C) and apoB (7). Potent CETP inhibition 
also modestly lowers TG levels; anacetrapib (100 mg/day) 
reduced TG by 6.8% (8) and evacetrapib (100 mg/day) by  
up to 7.9% (9) in dyslipidemic patients on background 
statin therapy. Large cohort studies have shown associations 
between genetic variation in CETP and CVD risk. Results 
from these large studies have identified polymorphisms that 
Abstract Cholesteryl ester transfer protein (CETP) medi-
ates the transfer of HDL cholesteryl esters for triglyceride 
(TG) in VLDL/LDL. CETP inhibition, with anacetrapib, 
increases HDL-cholesterol, reduces LDL-cholesterol, and 
lowers TG levels. This study describes the mechanisms re-
sponsible for TG lowering by examining the kinetics of 
VLDL-TG, apoC-II, apoC-III, and apoE. Mildly hypercholes-
terolemic subjects were randomized to either placebo (N = 
10) or atorvastatin 20 mg/qd (N = 29) for 4 weeks (period 1) 
followed by 8 weeks of anacetrapib, 100 mg/qd (period 2). 
Following each period, subjects underwent stable isotope 
metabolic studies to determine the fractional catabolic 
rates (FCRs) and production rates (PRs) of VLDL-TG and 
plasma apoC-II, apoC-III, and apoE. Anacetrapib reduced 
the VLDL-TG pool on a statin background due to an in-
creased VLDL-TG FCR (29%; P = 0.002). Despite an increased 
VLDL-TG FCR following anacetrapib monotherapy (41%; 
P = 0.11), the VLDL-TG pool was unchanged due to an 
increase in the VLDL-TG PR (39%; P = 0.014). apoC-II, 
apoC-III, and apoE pool sizes increased following anace-
trapib; however, the mechanisms responsible for these 
changes differed by treatment group. Anacetrapib increased 
the VLDL-TG FCR by enhancing the lipolytic potential of 
VLDL, which lowered the VLDL-TG pool on atorvastatin 
background.  There was no change in the VLDL-TG pool in 
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patient-oriented and epidemiological research
Effects of CETP inhibition on VLDL-TG metabolism 1215
result in reduced CETP activity and are associated with re-
duced CVD risk (7). In addition, studies in animal models 
have shown beneficial effects of CETP inhibition on reduc-
ing the development of atherosclerosis (7). While these 
findings initially made CETP an attractive target for reduc-
ing CVD risk, subsequent studies with CETP inhibitors 
have  shown an apparent  lack of  efficacy or harm due  to 
off-target effects, leading to increased uncertainty around 
the hypothesis that CETP reduces CVD risk (7, 10, 11).
Anacetrapib is a CETP inhibitor that is currently being 
evaluated in a phase 3 trial to determine its effects on 
cardiovascular protection when added to a statin (12). We 
have previously reported that CETP inhibition has the ef-
fects of enhancing VLDL and LDL apoB clearance while 
reducing the clearance of HDL apoA-I (4, 5), changes that 
are thought to reduce atherosclerotic risk. In the case of 
VLDL apoB, we speculated that CETP inhibition resulted 
in the formation of a TG-enriched VLDL particle that was 
an optimal substrate for lipoprotein lipase-mediated lipolysis 
and, hence, the increase in VLDL apoB fractional catabolic 
rate (FCR).  If  this was  indeed the case, we hypoth esized 
that CETP inhibition should enhance clearance of TG from 
VLDL over and above what is seen during the baseline pe-
riod. The current  study was conducted  to determine  the 
effects of CETP inhibition with anacetrapib on the produc-
tion and clearance of VLDL-TG. We also measured the me-
tabolism of apoC-II, apoC-III, and apoE, three proteins that 
affect VLDL lipolysis and clearance from the circulation.
MATERIALS AND METHODS
Study subjects/design
Thirty-nine mildly  hypercholesterolemic  subjects  were  en-
rolled at Columbia University Medical Center and the University 
of Pennsylvania. A detailed study design has been reported previ-
ously  (4)  (ClinicalTrials.gov  identifier  NCT00990808;  MK0859 
PN026). This study protocol is included in the supplemental ma-
terials. Subject characteristics at  screening are shown in supple-
mental Table S1. Subjects were randomized  to either panel A 
(anacetrapib plus statin background treatment) or panel B (anac-
etrapib monotherapy plus background of placebo) in a 3:1 ratio 
according to a computer-generated allocation schedule strati-
fied by LDL-C levels <160 mg/dl or 160 mg/dl to ensure a bal-














bridge Isotope Laboratories, Cambridge, MA) over a 15 h period 
under  continuous  feeding  conditions.  Blood  samples  were  col-
lected at 0 (pre-bolus), 20, and 40 min, and at 1, 2, 4, 6, 8, 10, 12, 
14, 15, 15.5, 16, 18, 21, 24, and 48 h post-bolus to determine apo-
lipoprotein and TG kinetics.
















VLDL-TG  enrichment  with  [1,1,2,3,3-2H5]glycerol  was  mea-
sured by the Metabolic Tracer Resource at the University of Penn-
sylvania and at the Irving Institute for Clinical and Translational 
Research core resource laboratory at Columbia University Medi-
cal Center (14). VLDL (d < 1.006 g/ml) was isolated by ultracen-
trifugation from blood samples collected throughout the kinetic 






fitting the stable isotope-labeled glycerol enrichment data to a mul-
ticompartmental model using a weighted least-squares approach 
with  WinSAAM  version  3.0.7.  The  multicompartmental  model 
was identical to that previously reported for apoB (4). Transfer 
rates  between  compartments were  constrained  to  values  deter-
mined  for  apoB, while  rates  for  direct  clearance were  variable 
(16). The hepatic TG precursor was represented by the plasma 
[1,1,2,3,3-2H5]glycerol enrichment or, if unavailable, a reference 
plasma glycerol model (16). The FCR of VLDL-TG was calculated 
from kinetic parameters as the fraction of TG cleared from plasma 
per day. The production rate (PR) for VLDL-TG was calculated as 
the product of the FCR and the plasma pool size, which was calcu-
lated as the product of the average VLDL-TG concentration, mea-
sured at a minimum of three time points during the metabolic 
study, and the plasma volume, assumed to be 4.5% of body weight.
apoC-II, apoC-III, and apoE kinetics
apoC-II, apoC-III and apoE analyses were prepared for LC-MS 
using a method published previously (17) but modified to reduce 
trypsin volume requirements and to achieve maximum digestion 
efficiency while reducing the overall cost of analysis (18). Briefly, 
20 l of plasma was diluted and digested with trypsin overnight, 
prior to analysis performed by ultra-performance LC combined 
with a triple quadrupole MS using multiple reaction monitoring 
to measure isotope enrichment. apoC-II, apoC-III, and apoE ki-
netic parameters were individually determined by fitting the sta-
ble isotope-labeled leucine tracer data to a multicompartmental 
model using a weighted least-squares approach using WinSAAM 
version 3.0.7. The multicompartmental model consisted of three 
compartments: a hepatic precursor, a synthetic delay, and plasma 
protein (apoC-II, apoC-III, or apoE). The hepatic precursor was 
represented  by  the  plasma  [5,5,5-2H3]leucine enrichment. The 
FCR of each protein was calculated from kinetic parameters as the 
fraction of protein cleared from plasma per day. The PR for each 
protein was calculated as the product of the FCR and the plasma 
pool size measured at a minimum of three time points during the 
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metabolic study, and the plasma volume, assumed to be 4.5% of 
body weight.
Statistics
All  statistical  analyses  were  conducted  using  SAS®  software 
(SAS Institute Inc., Cary, NC). Analysis was performed on log-
scale and the estimates obtained were back-transformed using the 










ods. Hodges-Lehmann estimates based on Wilcoxon signed rank 
test and corresponding P values were reported for treatment pe-












The baseline characteristics of the subjects participating 
in this study have been reported previously (4). Briefly, 
39 subjects completed the study. Subjects completing the 
study were predominantly male (67%) with a mean age 









VLDL-TG response to anacetrapib monotherapy or on 
background statin treatment
Anacetrapib treatment significantly reduced the VLDL-TG 
pool size by 14% in the subjects treated on an atorvas-
tatin background. This was due to a significant 29% in-







increased VLDL-TG FCR  (40%, P = 0.11) and increased 
VLDL-TG PR (39%, P = 0.01). The ratio of VLDL-TG 
PR/VLDL  apoB100  PR  provides  a measure  of  the  TG 
content of newly secreted VLDL. The VLDL-TG PR/VLDL 
apoB100 PR ratio increased by 18% in subjects treated on 
an atorvastatin background. In contrast, subjects treated 
with anacetrapib monotherapy showed no significant change 
in the VLDL-TG PR/VLDL apoB100 PR ratio.
Plasma apoC-II, apoC-III, and apoE kinetic response to 
anacetrapib monotherapy or anacetrapib plus background 
statin treatment
The plasma apoE pool size increased by 22% in subjects 
on anacetrapib plus statin (P = 0.015). This was due to a 












pool size (P = 0.05). Despite the increase in apoC-II pool 
size, no detectible changes in either the apoC-II FCR or PR 
were observed.
The apoC-III PS increased by 31% in response to anac-
etrapib plus statin (P = 0.012). There was no significant 
change in the apoC-III FCR, while the apoC-III PR trended 




(P = 0.027) and a nonsignificant increase in the apoC-III PR.
Because an increase in plasma apoC-III is typically ac-
companied by reduced clearance of VLDL-TG, we exam-
ined the distribution of apoC-III among the VLDL and 
HDL lipoprotein fractions isolated by ultracentrifugation. 
In both treatment panels  there were significant reduc-
tions in the amount of apoC-III in the VLDL fraction 
(Table 4). This was accompanied by a significant increase 
in the amount of apoC-III in the HDL fraction.
TABLE  1.  Baseline lipid data following background statin (panel A) 
or placebo (panel B) treatment
Characteristic
Panel A  
(N = 29)




TC (mg/dl) 163 209 184
 Geometric mean (% CV) (13) (17) (17)
TGs (mg/dl) 89 121 104
 Geometric mean (% CV) (38) (59) (44)
LDL-C (mg/dl) 90 134 93
 Median (IQR) (16) (23) (39)
HDL-C (mg/dl) 48 43 48
 Median (IQR) (19) (20) (20)
apoC-II (mg/dl) 4.4 5.2 4.4
 Median (IQR) (1.3) (3.1) (1.5)
apoC-III (mg/dl) 7.4 8.4 7.9
 Geometric mean (% CV) (40.8) (35.2) (39.4)
apoE (mg/dl) 3.3 4.4 3.7
 Median (IQR) (0.8) (0.8) (0.8)


















































































































































































































































































































































































































































































































































































































































































































































































































































CETP mediates the net exchange of TG on VLDL for CE 
on HDL. While CETP inhibition might be expected to in-
crease plasma TG levels due to inhibition of TG transfer 
out of VLDL (6), plasma TG levels have been reported to 
be reduced following potent CETP inhibition with anace-
trapib (8). A reduction in plasma TG levels seen in response 
to CETP inhibition may be due to a reduced VLDL-TG PR 
or increased clearance of VLDL-TG. In the latter case, in-
creases in either lipolysis or direct removal of TGs in VLDL 
remnants by the liver would both have the effect of lower-
ing VLDL-TG levels. The current study was conducted to 
assess the mechanism responsible for changes in VLDL-TG 
in response to CETP inhibition with anacetrapib.
We  found  that  CETP  inhibition  with  anacetrapib  en-
hanced fractional catabolism of VLDL-TG both on back-
ground statin treatment and when anacetrapib was given as 
monotherapy. On the background of statin treatment, a 








of VLDL-TG to HDL may result in larger TG-rich VLDLs, 
which are better substrates for lipoprotein lipase than smaller 
particles (19). Second, CETP inhibition may lead to an in-
crease in lipoprotein lipase mass with greater  lipolysis of 
VLDL-TGs. Third, the reduced transfer of VLDL-TG to HDL 
in response to CETP inhibition may result in a redistribution 
of exchangeable apolipoproteins on VLDL and HDL, which 
could enhance the in vivo activity of lipoprotein lipase or 
facilitate direct hepatic removal of VLDL remnants.
The ratio of the VLDL-TG and apoB PRs can be used as 
a measure of the TG content of newly secreted VLDL par-
ticles. Our results  indicated  that  there was a modest, but 






ute  to  the  increased  clearance  rate  of VLDL-TG  that we 
measured in subjects on a background of statin treatment, 
but not with anacetrapib monotherapy. Mice treated with 
anacetrapib showed no change in the VLDL-TG or apoB 




anacetrapib (4). This indicates that a change in lipoprotein 
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in response to anacetrapib treatment, circulating VLDL is 
relatively enriched with TG and depleted of cholesterol. 
Cholesterol  has  been  reported  to  lower  the  activity  of 
lipoprotein lipase against TG-enriched emulsions (22). 
This is thought to be due to effects of cholesterol on limit-
ing availability of TG on the outer phospholipid layer of 
the VLDL particle surface (23), which leads to reduced 
TG lipolysis (24). The cholesterol content of VLDL can 
also influence particle affinity for apolipoproteins that 
regulate  lipoprotein  lipase  activity  (22),  as well  as  the 
particle affinity of lipoprotein lipase (25).
VLDL-TG metabolism is regulated by both the activity of 
lipoprotein lipase, which is controlled by a number of ex-
changeable apolipoproteins, including apoC-II and C-III, 
and whole particle VLDL uptake by lipoprotein receptors, 
controlled, in part, by apoE and apoC-III. We measured the 
changes in these apolipoproteins to determine their role 
in potential downstream effects on VLDL-TG metabolism. 
There was  an  increase  in  the  apoE pool  size  in  subjects 
treated with anacetrapib on a background of atorvastatin, 
but not when used as a monotherapy. Bisgaier et al. (26) 
conducted in vitro studies examining the effect of CETP 







the conversion of VLDL-apoB to LDL-apoB after anacetra-
pib treatment (4). This suggests that anacetrapib treatment 




vate and inhibit lipoprotein lipase, respectively. Anacetra-
pib  treatment  increased  apoC-II  and  apoC-III  pool  sizes 
both when used as a monotherapy and on an atorvastatin 
background. The increase of the apoC-II pool is unlikely to 
promote further activity of lipoprotein lipase beyond what 
is observed during the baseline period. Minimal amounts 
of apoC-II are required to activate lipoprotein lipase be-
yond which  there  is no apparent  increase  in activity  (27, 
28). Shachter et al. (29) have shown that overexpression of 






to result in an increase in plasma TG levels by inhibiting 
both VLDL clearance and lipoprotein lipase. In our study, 
the opposite effect on plasma TG levels was observed. We 
found that this was due to a shift of apoC-III particles from 
VLDL to HDL in response to anacetrapib treatment, 
an effect likely due to an increase in the surface area of 
HDL. A similar redistribution in apoC-III from VLDL to 
HDL was seen by Krauss et al. (21) in response to anacetrapib 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































reduces the inhibitory effect of apoC-III on lipolysis of 
VLDL-TG, consistent with what we observed in the current 
study. Krauss et al. (21) reported that the increase in HDL 
apoC-III following anacetrapib treatment was greater than 
100%, whereas the increase in HDL apoE was 50%. This 
indicates that there may be a greater reduction in apoC-III 
than  apoE  in  VLDL,  which  may  enhance  lipolysis  of  
TG on VLDL. While anacetrapib has not been tested in 
patients with hypertriglyceridemia,  a  similar TG-lowering 
effect would be expected  in patients with elevated TG 
levels resulting from excessive apoC-III.
In an effort to further understand the regulation of TG 
metabolism  following  anacetrapib  treatment, we  studied 
the kinetics of apoC-II, apoC-III, and apoE. Our findings 
varied between the groups of statin background and mono-
therapy.  In  subjects  treated  with  anacetrapib  on  a  statin 
background, apoC-II, apoC-III, and apoE pool  sizes were 
all significantly increased. Because these apolipoproteins 
exchange between VLDL and HDL, it might be expected 
that the increase in pool sizes of these constituents would 







in statin-treated subjects in response to the CETP inhibitor, 
torcetrapib (30). An increase in apoE and apoC-III produc-
tion could be due to a direct effect of anacetrapib on APOE 
and APOC3 expression in the liver or could be secondary 
to effects on expression due to enhanced delivery of lipids 
from apoB-containing lipoproteins and HDL to liver. In 
subjects  treated with anacetrapib monotherapy, we ob-
served a significant increase in the apoC-II and apoC-III 
pool sizes. In contrast to what was seen in statin-treated sub-
jects,  the  increase  in  the apoC-III pool size  in  the mono-
therapy group was due to a reduction in the apoC-III FCR. 
It should be noted that in both the statin-treated and mono-
therapy groups, while not always significant, there were re-
ductions in the apoC-III FCR and an increase in the PR, so 
both mechanisms may be contributing to the increase in 
apoC-III pool size following anacetrapib treatment.
The clinical implications of these findings are not read-
ily  apparent.  CETP  inhibition  with  other  candidates  did 
not  result  in cardiovascular benefit when compared with 
statin treatment (10, 11, 31) for reasons that have been dis-
cussed (32). Anacetrapib is currently being evaluated in 
the REVEAL study to determine its effect on cardiovascu-
lar risk. If anacetrapib is found to be successful in reduc-
ing cardiovascular risk,  further studies will be needed to 
determine whether  the benefit  results  from reduction  in 
apoB-containing lipoproteins, TG, an increase in HDL, or 
some combination of beneficial changes.
In summary, anacetrapib treatment increases the FCR of 
VLDL-TG, likely by increasing the TG:cholesterol ratio on 
VLDL, and possibly the size of newly secreted VLDL, thus 
enhancing the lipolytic potential of VLDL. We found no 
evidence for an increase in apoC-III resulting in impaired 
1220 Journal of Lipid Research Volume 58, 2017
VLDL-TG clearance, most likely due to a shift in apoC-III 
from VLDL  to HDL. The  increase  in  the VLDL-TG FCR 
was associated with decreases  in VLDL-TG  levels when 
anacetrapib  was  added  to  atorvastatin  treatment.  There 
was no change, however, in VLDL-TG in subjects treated 
with  anacetrapib monotherapy due  to  an  accompanying 
similar increase in the VLDL-TG PR.
The authors thank Amy O. Levonas PhD. and Jennifer Rotonda 
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(Columbia University Medical Center), Anastasiya Matveyenko 
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